Recombinant human PDCD5 exhibits an antitumor role in hepatocellular carcinoma cells via clathrin‑dependent endocytosis.
Liver cancer is the fifth most frequently diagnosed type of cancer in men worldwide. Recombinant human programmed cell death 5 (rhPDCD5) has been shown to enter a variety of cells by clathrin-independent endocytosis. Tissue specimens from 32 hepatocellular carcinoma (HCC) patients were collected for analysis of PDCD5 expression using ELISA. It was confirmed that the pre‑operative serum levels of PDCD5 protein in patients with HCC were significantly lower than the post‑operative serum levels. Moreover, the serum PDCD5 levels were significantly correlated with portal invasion and lymph node metastasis. rhPDCD5 inhibited cell proliferation as indicated by an MTT assay, and induced apoptosis and S-phase arrest in HCC cells as demonstrated by flow cytometric analysis. Furthermore, rhPDCD5 suppressed tumor growth in established xenograft tumor models. In addition, Pitstop2 was used to block clathrin-dependent endocytosis (CDE), which confirmed that the anti‑tumor effect of rhPDCD5 in HCC cells is mediated via CDE.
Department of General Surgery, First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Da-Zhi
DZ
Fu
Department of General Surgery, First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Ying
Y
Cheng
Department of General Surgery, First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Hui
H
He
Department of General Surgery, First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Hai-Yang
HY
Liu
Department of General Surgery, First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Yong-Feng
YF
Liu
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D051017:Apoptosis Regulatory Proteins / Q000097:blood / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D004705:Endocytosis / Q000187:drug effects*; D005260:Female; D005818:Genetic Engineering; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000097:blood / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology*; D011993:Recombinant Fusion Proteins / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology; D053778:Thiazolidines / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D051017:Apoptosis Regulatory Proteins; D009363:Neoplasm Proteins; C117283:PDCD5 protein, human; D011993:Recombinant Fusion Proteins; D013449:Sulfonamides; D053778:Thiazolidines; C578512:pitstop 2